Global Breast Cancer Therapeutics Market Report 2022 to 2030

Global Breast Cancer Therapeutics Market Analysis

$ 3999

With an increase in breast cancer cases worldwide and rising investments in the research and development projects for breast cancer treatment, the Global breast cancer therapeutics market is expected to grow from $18.2 Bn in 2022 to $48.04 Bn in 2030 with a CAGR of 12.9% for the year 2022-2030. The market is segmented by therapy, by cancer type, and by distribution channel. Some of the key market players in the Global breast cancer therapeutics market are Sanofi, Pfizer, and AstraZeneca.

ID: IN10GLPH031 CATEGORY: Pharmaceuticals GEOGRAPHY: Global AUTHOR: Parul Choudhary

Buy Now

Global Breast Cancer Therapeutics Market Executive Analysis

The global breast cancer therapeutics market size is at around $18.2 Bn in 2022 and is projected to reach $48.04 Bn in 2030, exhibiting a CAGR of 12.9% during the forecast period. According to the National Trend Survey, insurers anticipate a 14.2% increase in healthcare expenses in Latin America and a 7.6% increase in the United States in 2022. Healthcare expenses are predicted to climb by 10.6% in the Middle East and Africa, 7.6% in the Asia-Pacific region, and 6.7% in Europe, according to stakeholders. More than 75% of medical insurers anticipate an increase in healthcare expenditures over the next three years, according to the survey. Over this time period, almost 86% of insurers in Europe anticipate significantly rising healthcare expenses, while 82% of insurers in the Middle East and Africa anticipate the same trend.

With 1 in 8 cancer diagnoses worldwide, breast cancer is the most frequently diagnosed cancer kind. Globally, there were around 2.3 Mn new cases of breast cancer in 2020, and there were also approximately 685,000 deaths from this illness, with significant regional variances between different nations and global areas. Although transitioning nations account for a disproportionate number of breast cancer deaths, these nations also have the greatest rates of breast cancer incidence. The most significant risk factor is age, and the oldest females have the highest age-specific incidence rates. Less than one in five women with breast cancer is diagnosed before the age of 50 in the UK, while more than one-third of cases affect women beyond the age of 70. In contrast, more than half of breast cancer cases in women under 50 years old occur in less developed nations.

Even in individuals at low risk of recurrence, adjuvant systemic medicines, including endocrine therapy, anti-HER2 therapy, and chemotherapy, are beneficial in lowering the risk of distant and local recurrence. Adjuvant systemic therapy is frequently used, which has helped to lower mortality rates from breast cancer. From single alkylating drugs to polychemotherapy regimens combining anthracyclines and/or taxanes, adjuvant cytotoxic chemotherapy regimens have undergone an evolution. Predicting the benefit of chemotherapy has proven to be more difficult, despite the fact that adjuvant therapies are frequently led by predictive indicators for endocrine therapy and anti-HER2 therapy.

global breast cancer therapeutics market analysis

Market Dynamics

Market Growth Drivers

The Global breast cancer therapeutics market will rise as the disease becomes more prevalent, especially in developed nations. For market players, the development of therapies with higher success rates is predicted to present profitable growth prospects. Pharmacies are becoming more interested in the breast cancer therapeutics area despite the hefty expenditures of research and development. This is anticipated to provide the Global breast cancer therapeutics market with excellent potential to grow.

Market Restraints

Adverse effects including nausea, diarrhea, mouth ulcers, skin conditions, and others may make it difficult for the Global breast cancer therapeutics market to expand in size as they become more severe and may have an impact on the lives of individuals and overall strength. The market size may change due to increased adverse events associated with immunotherapy and targeted chemotherapy. Chemotherapy is the most expensive therapy and because of the higher cost, not everyone can afford it, which could lead to a drop in the Global breast cancer therapeutics market share.

Competitive Landscape

Key Players

Kyowa Kirin
Sanofi
Pfizer
AstraZeneca
Eli Lilly
Eisai
F. Hoffmann-La Roche

Healthcare Policies and Regulatory Landscape

The expense of breast cancer treatment is covered by national health insurance plans in many nations, particularly in Europe and Asia. For some treatments, cost-sharing or co-pays can be necessary. Private health insurance might serve as the principal source of coverage for breast cancer therapy in nations without a universal health insurance system. Depending on the exact plan and the person's unique situation, the scope of coverage may change. The expense of breast cancer therapy may be covered by reimbursement programs in some nations. Programs that offer financial assistance to eligible patients or programs that offer compensation for the cost of specific therapies could fall under this category.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

Global Breast Cancer Therapeutics Segmentation

By Therapy (Revenue, USD Billion):

Radiation Therapy
- Targeted Therapy
  - Ribociclib
  - Abemaciclib
  - Afinitor
  - Everolimus
  - Trastuzumab
  - Olaparib
  - Ado-Trastuzumab Emtansine
  - Palbociclib
  - Pertuzumab
  - Herceptin
  - Tykerb (Lapatinib)
  - Others
Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)
Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents
Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Geography

APAC Breast Cancer Therapeutics Market

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
- Ribociclib
- Abemaciclib
- Afinitor
- Everolimus
- Trastuzumab
- Olaparib
- Ado-Trastuzumab Emtansine
- Palbociclib
- Pertuzumab
- Herceptin
- Tykerb (Lapatinib)
- Others

Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)

Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents

Immunotherapy

Europe Breast Cancer Therapeutics Market

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
- Ribociclib
- Abemaciclib
- Afinitor
- Everolimus
- Trastuzumab
- Olaparib
- Ado-Trastuzumab Emtansine
- Palbociclib
- Pertuzumab
- Herceptin
- Tykerb (Lapatinib)
- Others

Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)

Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents

Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

North America Breast Cancer Therapeutics Market

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
- Ribociclib
- Abemaciclib
- Afinitor
- Everolimus
- Trastuzumab
- Olaparib
- Ado-Trastuzumab Emtansine
- Palbociclib
- Pertuzumab
- Herceptin
- Tykerb (Lapatinib)
- Others

Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)

Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents

Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Middle East Breast Cancer Therapeutics Market

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
- Ribociclib
- Abemaciclib
- Afinitor
- Everolimus
- Trastuzumab
- Olaparib
- Ado-Trastuzumab Emtansine
- Palbociclib
- Pertuzumab
- Herceptin
- Tykerb (Lapatinib)
- Others

Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)

Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents

Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Africa Breast Cancer Therapeutics Market

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
- Ribociclib
- Abemaciclib
- Afinitor
- Everolimus
- Trastuzumab
- Olaparib
- Ado-Trastuzumab Emtansine
- Palbociclib
- Pertuzumab
- Herceptin
- Tykerb (Lapatinib)
- Others

Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)

Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents

Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Latin America Breast Cancer Therapeutics Market

By Therapy (Revenue, USD Billion):

Radiation Therapy
Targeted Therapy
- Ribociclib
- Abemaciclib
- Afinitor
- Everolimus
- Trastuzumab
- Olaparib
- Ado-Trastuzumab Emtansine
- Palbociclib
- Pertuzumab
- Herceptin
- Tykerb (Lapatinib)
- Others

Hormonal Therapy
- Selective Estrogen Receptor Modulators (SERMs)
- Aromatase Inhibitors
- Estrogen Receptor Downregulators (ERDs)

Chemotherapy
- Taxanes
- Anthracyclines
- Anti-metabolites
- Alkylating Agents

Immunotherapy

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

By Cancer Type (Revenue, USD Billion):

Hormone Receptor
HER+

By Distribution Channel (Revenue, USD Billion):

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Others

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

Analyzing historical proprietary data collected from multiple projects.
Regularly updating our existing data sets with new findings and trends.
Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

Searching through academic conferences, published research, citations, and social media platforms
Collecting and compiling diverse data to build a comprehensive and detailed database
Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
Continuously refreshing our database to ensure that the information remains current and reliable.
Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

Merging historical data from secondary research with real-time data from primary research.
Conducting thorough data validation and cleansing to remove inconsistencies and errors.
Organizing data into a structured format that is easily accessible and usable for various applications.
Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.